Mike Allen has over 35 years of UK and Global pharmaceutical industry experience within the field of antibiotics, antimicrobial resistance and infectious disease. Mike started his career as a clinical pharmacologist working with the Pain & Opiate Research Group at the Nuffield Department of Anaesthetics in Oxford from 1979 to 1986.
Following appointments in Lederle Laboratories (later became Wyeth Pharmaceuticals), Novartis Pharmaceuticals and Cubist, Mike currently works as the Regional Medical Advisor (Antibiotics) and MSD Ltd UK, with medical responsibilities for MSD’s broad portfolio of licensed antibiotics and pipeline molecules. Over his career in the pharmaceutical industry, he has worked collaboratively with the medical, commercial, policy and development teams at National, European and Global levels, including the coordination of a highly successful international antibiotic registry and multiple clinical and in vitro antibiotic studies.
Mike was elected to serve his first 3-year term as General Secretary of BSAC in 2022 and re-elected in 2025 to serve a further 3-year term. Mike has been an Ordinary Member of BSAC Council since 2018, having previously served as an Ordinary Member of Council from 2012-2015. He is a member of the BSAC Resistance Surveillance Project (BSAC RSP) Legacy Working Group, having served on the BSAC RSP Steering Committee since the inception of the project in 1999, initially as an industry representative and from 2010 as a core member.
Mike has co-authored over 40 publications with lead researchers in the UK and internationally, looking particularly at antibiotic resistance surveillance and the association between antibiotic use and infections caused by clinically significant pathogens including; Clostridium difficile, glycopeptide-resistant enterococci, MRSA, Pseudomonas aeruginosa and ESBL-producing Enterobacterales